Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2013–2014

•A total of 10,641 influenza viruses were collected worldwide, May 2013–May 2014.•Approximately 2% showed highly reduced inhibition by at least one NA inhibitor.•NA inhibitors remain an appropriate choice for influenza treatment and prophylaxis.•Global surveillance of influenza antiviral susceptibil...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Antiviral research 2015-05, Vol.117, p.27-38
Hauptverfasser: Takashita, Emi, Meijer, Adam, Lackenby, Angie, Gubareva, Larisa, Rebelo-de-Andrade, Helena, Besselaar, Terry, Fry, Alicia, Gregory, Vicky, Leang, Sook-Kwan, Huang, Weijuan, Lo, Janice, Pereyaslov, Dmitriy, Siqueira, Marilda M., Wang, Dayan, Mak, Gannon C., Zhang, Wenqing, Daniels, Rod S., Hurt, Aeron C., Tashiro, Masato
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 38
container_issue
container_start_page 27
container_title Antiviral research
container_volume 117
creator Takashita, Emi
Meijer, Adam
Lackenby, Angie
Gubareva, Larisa
Rebelo-de-Andrade, Helena
Besselaar, Terry
Fry, Alicia
Gregory, Vicky
Leang, Sook-Kwan
Huang, Weijuan
Lo, Janice
Pereyaslov, Dmitriy
Siqueira, Marilda M.
Wang, Dayan
Mak, Gannon C.
Zhang, Wenqing
Daniels, Rod S.
Hurt, Aeron C.
Tashiro, Masato
description •A total of 10,641 influenza viruses were collected worldwide, May 2013–May 2014.•Approximately 2% showed highly reduced inhibition by at least one NA inhibitor.•NA inhibitors remain an appropriate choice for influenza treatment and prophylaxis.•Global surveillance of influenza antiviral susceptibility should be continued. Four World Health Organization (WHO) Collaborating Centres for Reference and Research on Influenza and one WHO Collaborating Centre for the Surveillance, Epidemiology and Control of Influenza (WHO CCs) tested 10,641 viruses collected by WHO-recognized National Influenza Centres between May 2013 and May 2014 to determine 50% inhibitory concentration (IC50) data for neuraminidase inhibitors (NAIs) oseltamivir, zanamivir, peramivir and laninamivir. In addition, neuraminidase (NA) sequence data, available from the WHO CCs and from sequence databases (n=3206), were screened for amino acid substitutions associated with reduced NAI susceptibility. Ninety-five per cent of the viruses tested by the WHO CCs were from three WHO regions: Western Pacific, the Americas and Europe. Approximately 2% (n=172) showed highly reduced inhibition (HRI) against at least one of the four NAIs, commonly oseltamivir, while 0.3% (n=32) showed reduced inhibition (RI). Those showing HRI were A(H1N1)pdm09 with NA H275Y (n=169), A(H3N2) with NA E119V (n=1), B/Victoria-lineage with NA E117G (n=1) and B/Yamagata-lineage with NA H273Y (n=1); amino acid position numbering is A subtype and B type specific. Although approximately 98% of circulating viruses tested during the 2013–2014 period were sensitive to all four NAIs, a large community cluster of A(H1N1)pdm09 viruses with the NA H275Y substitution from patients with no previous exposure to antivirals was detected in Hokkaido, Japan. Significant numbers of A(H1N1)pdm09 NA H275Y viruses were also detected in China and the United States: phylogenetic analyses showed that the Chinese viruses were similar to those from Japan, while the United States viruses clustered separately from those of the Hokkaido outbreak, indicative of multiple resistance-emergence events. Consequently, global surveillance of influenza antiviral susceptibility should be continued from a public health perspective.
doi_str_mv 10.1016/j.antiviral.2015.02.003
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9036627</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0166354215000315</els_id><sourcerecordid>1732833252</sourcerecordid><originalsourceid>FETCH-LOGICAL-c574t-b91ce27f8f490c738ff88e2e8cfcbdac8b33cd54910b2a10505db735a9d370bb3</originalsourceid><addsrcrecordid>eNqFkc1u1DAUhS0EokPhFcBLFiT4J4mdDVJV0YJUiQ2sLdu56XiU2IN_Rior3oE35EnqasoIVqzu4n7nnKt7EHpDSUsJHd7vWu2zO7iol5YR2reEtYTwJ2hDpWDNSMbhKdpUcmh437Ez9CKlHSFkEKN8js5YLxjtpNyg2-slGL3gsp90Bhw8zlvAqSQL--yMW1y-w2HG27Jqj52flwL-h8Y1uiRIOAfsoUS9Ou8mnaAi2yrLIaZ3uF7Gf__8VUf3Ej2b9ZLg1eM8R9-uPn69_NTcfLn-fHlx09hedLkxI7XAxCznbiRWcDnPUgIDaWdrJm2l4dxOfTdSYpimpCf9ZATv9ThxQYzh5-jD0XdfzAqTBZ_rj9Q-ulXHOxW0U_9uvNuq23BQI-HDwEQ1ePtoEMP3Aimr1dVnLIv2EEpSVHAmOWc9q6g4ojaGlCLMpxhK1ENNaqdONamHmhRhqtZUla__vvKk-9NLBS6OANRfHRxElawDb2FyEWxWU3D_DbkHZ4Krtw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1732833252</pqid></control><display><type>article</type><title>Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2013–2014</title><source>MEDLINE</source><source>ScienceDirect Journals (5 years ago - present)</source><creator>Takashita, Emi ; Meijer, Adam ; Lackenby, Angie ; Gubareva, Larisa ; Rebelo-de-Andrade, Helena ; Besselaar, Terry ; Fry, Alicia ; Gregory, Vicky ; Leang, Sook-Kwan ; Huang, Weijuan ; Lo, Janice ; Pereyaslov, Dmitriy ; Siqueira, Marilda M. ; Wang, Dayan ; Mak, Gannon C. ; Zhang, Wenqing ; Daniels, Rod S. ; Hurt, Aeron C. ; Tashiro, Masato</creator><creatorcontrib>Takashita, Emi ; Meijer, Adam ; Lackenby, Angie ; Gubareva, Larisa ; Rebelo-de-Andrade, Helena ; Besselaar, Terry ; Fry, Alicia ; Gregory, Vicky ; Leang, Sook-Kwan ; Huang, Weijuan ; Lo, Janice ; Pereyaslov, Dmitriy ; Siqueira, Marilda M. ; Wang, Dayan ; Mak, Gannon C. ; Zhang, Wenqing ; Daniels, Rod S. ; Hurt, Aeron C. ; Tashiro, Masato</creatorcontrib><description>•A total of 10,641 influenza viruses were collected worldwide, May 2013–May 2014.•Approximately 2% showed highly reduced inhibition by at least one NA inhibitor.•NA inhibitors remain an appropriate choice for influenza treatment and prophylaxis.•Global surveillance of influenza antiviral susceptibility should be continued. Four World Health Organization (WHO) Collaborating Centres for Reference and Research on Influenza and one WHO Collaborating Centre for the Surveillance, Epidemiology and Control of Influenza (WHO CCs) tested 10,641 viruses collected by WHO-recognized National Influenza Centres between May 2013 and May 2014 to determine 50% inhibitory concentration (IC50) data for neuraminidase inhibitors (NAIs) oseltamivir, zanamivir, peramivir and laninamivir. In addition, neuraminidase (NA) sequence data, available from the WHO CCs and from sequence databases (n=3206), were screened for amino acid substitutions associated with reduced NAI susceptibility. Ninety-five per cent of the viruses tested by the WHO CCs were from three WHO regions: Western Pacific, the Americas and Europe. Approximately 2% (n=172) showed highly reduced inhibition (HRI) against at least one of the four NAIs, commonly oseltamivir, while 0.3% (n=32) showed reduced inhibition (RI). Those showing HRI were A(H1N1)pdm09 with NA H275Y (n=169), A(H3N2) with NA E119V (n=1), B/Victoria-lineage with NA E117G (n=1) and B/Yamagata-lineage with NA H273Y (n=1); amino acid position numbering is A subtype and B type specific. Although approximately 98% of circulating viruses tested during the 2013–2014 period were sensitive to all four NAIs, a large community cluster of A(H1N1)pdm09 viruses with the NA H275Y substitution from patients with no previous exposure to antivirals was detected in Hokkaido, Japan. Significant numbers of A(H1N1)pdm09 NA H275Y viruses were also detected in China and the United States: phylogenetic analyses showed that the Chinese viruses were similar to those from Japan, while the United States viruses clustered separately from those of the Hokkaido outbreak, indicative of multiple resistance-emergence events. Consequently, global surveillance of influenza antiviral susceptibility should be continued from a public health perspective.</description><identifier>ISSN: 0166-3542</identifier><identifier>EISSN: 1872-9096</identifier><identifier>DOI: 10.1016/j.antiviral.2015.02.003</identifier><identifier>PMID: 25721488</identifier><language>eng</language><publisher>Netherlands: Elsevier B.V</publisher><subject>Acids, Carbocyclic ; Amino Acid Substitution ; Antiviral Agents - pharmacology ; Antiviral resistance ; China - epidemiology ; Cyclopentanes - pharmacology ; Disease Outbreaks - statistics &amp; numerical data ; Drug Resistance, Viral - genetics ; Enzyme Inhibitors - pharmacology ; Europe - epidemiology ; Global analysis ; Guanidines - pharmacology ; Humans ; Influenza A Virus, H1N1 Subtype - drug effects ; Influenza A Virus, H1N1 Subtype - genetics ; Influenza A Virus, H3N2 Subtype - drug effects ; Influenza A Virus, H3N2 Subtype - genetics ; Influenza B virus - drug effects ; Influenza B virus - genetics ; Influenza virus ; Inhibitory Concentration 50 ; Japan - epidemiology ; Microbial Sensitivity Tests ; Neuraminidase - antagonists &amp; inhibitors ; Neuraminidase - chemistry ; Neuraminidase - genetics ; Neuraminidase inhibitors ; Oseltamivir ; Oseltamivir - pharmacology ; Phylogeny ; Pyrans ; Reduced susceptibility ; Sialic Acids ; Time Factors ; United States - epidemiology ; World Health Organization ; Zanamivir - analogs &amp; derivatives ; Zanamivir - pharmacology</subject><ispartof>Antiviral research, 2015-05, Vol.117, p.27-38</ispartof><rights>2015 The Authors</rights><rights>Copyright © 2015 The Authors. Published by Elsevier B.V. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c574t-b91ce27f8f490c738ff88e2e8cfcbdac8b33cd54910b2a10505db735a9d370bb3</citedby><cites>FETCH-LOGICAL-c574t-b91ce27f8f490c738ff88e2e8cfcbdac8b33cd54910b2a10505db735a9d370bb3</cites><orcidid>0000-0002-9064-4699</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.antiviral.2015.02.003$$EHTML$$P50$$Gelsevier$$Hfree_for_read</linktohtml><link.rule.ids>230,315,781,785,886,3551,27929,27930,46000</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25721488$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Takashita, Emi</creatorcontrib><creatorcontrib>Meijer, Adam</creatorcontrib><creatorcontrib>Lackenby, Angie</creatorcontrib><creatorcontrib>Gubareva, Larisa</creatorcontrib><creatorcontrib>Rebelo-de-Andrade, Helena</creatorcontrib><creatorcontrib>Besselaar, Terry</creatorcontrib><creatorcontrib>Fry, Alicia</creatorcontrib><creatorcontrib>Gregory, Vicky</creatorcontrib><creatorcontrib>Leang, Sook-Kwan</creatorcontrib><creatorcontrib>Huang, Weijuan</creatorcontrib><creatorcontrib>Lo, Janice</creatorcontrib><creatorcontrib>Pereyaslov, Dmitriy</creatorcontrib><creatorcontrib>Siqueira, Marilda M.</creatorcontrib><creatorcontrib>Wang, Dayan</creatorcontrib><creatorcontrib>Mak, Gannon C.</creatorcontrib><creatorcontrib>Zhang, Wenqing</creatorcontrib><creatorcontrib>Daniels, Rod S.</creatorcontrib><creatorcontrib>Hurt, Aeron C.</creatorcontrib><creatorcontrib>Tashiro, Masato</creatorcontrib><title>Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2013–2014</title><title>Antiviral research</title><addtitle>Antiviral Res</addtitle><description>•A total of 10,641 influenza viruses were collected worldwide, May 2013–May 2014.•Approximately 2% showed highly reduced inhibition by at least one NA inhibitor.•NA inhibitors remain an appropriate choice for influenza treatment and prophylaxis.•Global surveillance of influenza antiviral susceptibility should be continued. Four World Health Organization (WHO) Collaborating Centres for Reference and Research on Influenza and one WHO Collaborating Centre for the Surveillance, Epidemiology and Control of Influenza (WHO CCs) tested 10,641 viruses collected by WHO-recognized National Influenza Centres between May 2013 and May 2014 to determine 50% inhibitory concentration (IC50) data for neuraminidase inhibitors (NAIs) oseltamivir, zanamivir, peramivir and laninamivir. In addition, neuraminidase (NA) sequence data, available from the WHO CCs and from sequence databases (n=3206), were screened for amino acid substitutions associated with reduced NAI susceptibility. Ninety-five per cent of the viruses tested by the WHO CCs were from three WHO regions: Western Pacific, the Americas and Europe. Approximately 2% (n=172) showed highly reduced inhibition (HRI) against at least one of the four NAIs, commonly oseltamivir, while 0.3% (n=32) showed reduced inhibition (RI). Those showing HRI were A(H1N1)pdm09 with NA H275Y (n=169), A(H3N2) with NA E119V (n=1), B/Victoria-lineage with NA E117G (n=1) and B/Yamagata-lineage with NA H273Y (n=1); amino acid position numbering is A subtype and B type specific. Although approximately 98% of circulating viruses tested during the 2013–2014 period were sensitive to all four NAIs, a large community cluster of A(H1N1)pdm09 viruses with the NA H275Y substitution from patients with no previous exposure to antivirals was detected in Hokkaido, Japan. Significant numbers of A(H1N1)pdm09 NA H275Y viruses were also detected in China and the United States: phylogenetic analyses showed that the Chinese viruses were similar to those from Japan, while the United States viruses clustered separately from those of the Hokkaido outbreak, indicative of multiple resistance-emergence events. Consequently, global surveillance of influenza antiviral susceptibility should be continued from a public health perspective.</description><subject>Acids, Carbocyclic</subject><subject>Amino Acid Substitution</subject><subject>Antiviral Agents - pharmacology</subject><subject>Antiviral resistance</subject><subject>China - epidemiology</subject><subject>Cyclopentanes - pharmacology</subject><subject>Disease Outbreaks - statistics &amp; numerical data</subject><subject>Drug Resistance, Viral - genetics</subject><subject>Enzyme Inhibitors - pharmacology</subject><subject>Europe - epidemiology</subject><subject>Global analysis</subject><subject>Guanidines - pharmacology</subject><subject>Humans</subject><subject>Influenza A Virus, H1N1 Subtype - drug effects</subject><subject>Influenza A Virus, H1N1 Subtype - genetics</subject><subject>Influenza A Virus, H3N2 Subtype - drug effects</subject><subject>Influenza A Virus, H3N2 Subtype - genetics</subject><subject>Influenza B virus - drug effects</subject><subject>Influenza B virus - genetics</subject><subject>Influenza virus</subject><subject>Inhibitory Concentration 50</subject><subject>Japan - epidemiology</subject><subject>Microbial Sensitivity Tests</subject><subject>Neuraminidase - antagonists &amp; inhibitors</subject><subject>Neuraminidase - chemistry</subject><subject>Neuraminidase - genetics</subject><subject>Neuraminidase inhibitors</subject><subject>Oseltamivir</subject><subject>Oseltamivir - pharmacology</subject><subject>Phylogeny</subject><subject>Pyrans</subject><subject>Reduced susceptibility</subject><subject>Sialic Acids</subject><subject>Time Factors</subject><subject>United States - epidemiology</subject><subject>World Health Organization</subject><subject>Zanamivir - analogs &amp; derivatives</subject><subject>Zanamivir - pharmacology</subject><issn>0166-3542</issn><issn>1872-9096</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkc1u1DAUhS0EokPhFcBLFiT4J4mdDVJV0YJUiQ2sLdu56XiU2IN_Rior3oE35EnqasoIVqzu4n7nnKt7EHpDSUsJHd7vWu2zO7iol5YR2reEtYTwJ2hDpWDNSMbhKdpUcmh437Ez9CKlHSFkEKN8js5YLxjtpNyg2-slGL3gsp90Bhw8zlvAqSQL--yMW1y-w2HG27Jqj52flwL-h8Y1uiRIOAfsoUS9Ou8mnaAi2yrLIaZ3uF7Gf__8VUf3Ej2b9ZLg1eM8R9-uPn69_NTcfLn-fHlx09hedLkxI7XAxCznbiRWcDnPUgIDaWdrJm2l4dxOfTdSYpimpCf9ZATv9ThxQYzh5-jD0XdfzAqTBZ_rj9Q-ulXHOxW0U_9uvNuq23BQI-HDwEQ1ePtoEMP3Aimr1dVnLIv2EEpSVHAmOWc9q6g4ojaGlCLMpxhK1ENNaqdONamHmhRhqtZUla__vvKk-9NLBS6OANRfHRxElawDb2FyEWxWU3D_DbkHZ4Krtw</recordid><startdate>20150501</startdate><enddate>20150501</enddate><creator>Takashita, Emi</creator><creator>Meijer, Adam</creator><creator>Lackenby, Angie</creator><creator>Gubareva, Larisa</creator><creator>Rebelo-de-Andrade, Helena</creator><creator>Besselaar, Terry</creator><creator>Fry, Alicia</creator><creator>Gregory, Vicky</creator><creator>Leang, Sook-Kwan</creator><creator>Huang, Weijuan</creator><creator>Lo, Janice</creator><creator>Pereyaslov, Dmitriy</creator><creator>Siqueira, Marilda M.</creator><creator>Wang, Dayan</creator><creator>Mak, Gannon C.</creator><creator>Zhang, Wenqing</creator><creator>Daniels, Rod S.</creator><creator>Hurt, Aeron C.</creator><creator>Tashiro, Masato</creator><general>Elsevier B.V</general><scope>6I.</scope><scope>AAFTH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T2</scope><scope>7T7</scope><scope>7U2</scope><scope>7U9</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>H94</scope><scope>P64</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-9064-4699</orcidid></search><sort><creationdate>20150501</creationdate><title>Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2013–2014</title><author>Takashita, Emi ; Meijer, Adam ; Lackenby, Angie ; Gubareva, Larisa ; Rebelo-de-Andrade, Helena ; Besselaar, Terry ; Fry, Alicia ; Gregory, Vicky ; Leang, Sook-Kwan ; Huang, Weijuan ; Lo, Janice ; Pereyaslov, Dmitriy ; Siqueira, Marilda M. ; Wang, Dayan ; Mak, Gannon C. ; Zhang, Wenqing ; Daniels, Rod S. ; Hurt, Aeron C. ; Tashiro, Masato</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c574t-b91ce27f8f490c738ff88e2e8cfcbdac8b33cd54910b2a10505db735a9d370bb3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Acids, Carbocyclic</topic><topic>Amino Acid Substitution</topic><topic>Antiviral Agents - pharmacology</topic><topic>Antiviral resistance</topic><topic>China - epidemiology</topic><topic>Cyclopentanes - pharmacology</topic><topic>Disease Outbreaks - statistics &amp; numerical data</topic><topic>Drug Resistance, Viral - genetics</topic><topic>Enzyme Inhibitors - pharmacology</topic><topic>Europe - epidemiology</topic><topic>Global analysis</topic><topic>Guanidines - pharmacology</topic><topic>Humans</topic><topic>Influenza A Virus, H1N1 Subtype - drug effects</topic><topic>Influenza A Virus, H1N1 Subtype - genetics</topic><topic>Influenza A Virus, H3N2 Subtype - drug effects</topic><topic>Influenza A Virus, H3N2 Subtype - genetics</topic><topic>Influenza B virus - drug effects</topic><topic>Influenza B virus - genetics</topic><topic>Influenza virus</topic><topic>Inhibitory Concentration 50</topic><topic>Japan - epidemiology</topic><topic>Microbial Sensitivity Tests</topic><topic>Neuraminidase - antagonists &amp; inhibitors</topic><topic>Neuraminidase - chemistry</topic><topic>Neuraminidase - genetics</topic><topic>Neuraminidase inhibitors</topic><topic>Oseltamivir</topic><topic>Oseltamivir - pharmacology</topic><topic>Phylogeny</topic><topic>Pyrans</topic><topic>Reduced susceptibility</topic><topic>Sialic Acids</topic><topic>Time Factors</topic><topic>United States - epidemiology</topic><topic>World Health Organization</topic><topic>Zanamivir - analogs &amp; derivatives</topic><topic>Zanamivir - pharmacology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Takashita, Emi</creatorcontrib><creatorcontrib>Meijer, Adam</creatorcontrib><creatorcontrib>Lackenby, Angie</creatorcontrib><creatorcontrib>Gubareva, Larisa</creatorcontrib><creatorcontrib>Rebelo-de-Andrade, Helena</creatorcontrib><creatorcontrib>Besselaar, Terry</creatorcontrib><creatorcontrib>Fry, Alicia</creatorcontrib><creatorcontrib>Gregory, Vicky</creatorcontrib><creatorcontrib>Leang, Sook-Kwan</creatorcontrib><creatorcontrib>Huang, Weijuan</creatorcontrib><creatorcontrib>Lo, Janice</creatorcontrib><creatorcontrib>Pereyaslov, Dmitriy</creatorcontrib><creatorcontrib>Siqueira, Marilda M.</creatorcontrib><creatorcontrib>Wang, Dayan</creatorcontrib><creatorcontrib>Mak, Gannon C.</creatorcontrib><creatorcontrib>Zhang, Wenqing</creatorcontrib><creatorcontrib>Daniels, Rod S.</creatorcontrib><creatorcontrib>Hurt, Aeron C.</creatorcontrib><creatorcontrib>Tashiro, Masato</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Health and Safety Science Abstracts (Full archive)</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Safety Science and Risk</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Antiviral research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Takashita, Emi</au><au>Meijer, Adam</au><au>Lackenby, Angie</au><au>Gubareva, Larisa</au><au>Rebelo-de-Andrade, Helena</au><au>Besselaar, Terry</au><au>Fry, Alicia</au><au>Gregory, Vicky</au><au>Leang, Sook-Kwan</au><au>Huang, Weijuan</au><au>Lo, Janice</au><au>Pereyaslov, Dmitriy</au><au>Siqueira, Marilda M.</au><au>Wang, Dayan</au><au>Mak, Gannon C.</au><au>Zhang, Wenqing</au><au>Daniels, Rod S.</au><au>Hurt, Aeron C.</au><au>Tashiro, Masato</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2013–2014</atitle><jtitle>Antiviral research</jtitle><addtitle>Antiviral Res</addtitle><date>2015-05-01</date><risdate>2015</risdate><volume>117</volume><spage>27</spage><epage>38</epage><pages>27-38</pages><issn>0166-3542</issn><eissn>1872-9096</eissn><abstract>•A total of 10,641 influenza viruses were collected worldwide, May 2013–May 2014.•Approximately 2% showed highly reduced inhibition by at least one NA inhibitor.•NA inhibitors remain an appropriate choice for influenza treatment and prophylaxis.•Global surveillance of influenza antiviral susceptibility should be continued. Four World Health Organization (WHO) Collaborating Centres for Reference and Research on Influenza and one WHO Collaborating Centre for the Surveillance, Epidemiology and Control of Influenza (WHO CCs) tested 10,641 viruses collected by WHO-recognized National Influenza Centres between May 2013 and May 2014 to determine 50% inhibitory concentration (IC50) data for neuraminidase inhibitors (NAIs) oseltamivir, zanamivir, peramivir and laninamivir. In addition, neuraminidase (NA) sequence data, available from the WHO CCs and from sequence databases (n=3206), were screened for amino acid substitutions associated with reduced NAI susceptibility. Ninety-five per cent of the viruses tested by the WHO CCs were from three WHO regions: Western Pacific, the Americas and Europe. Approximately 2% (n=172) showed highly reduced inhibition (HRI) against at least one of the four NAIs, commonly oseltamivir, while 0.3% (n=32) showed reduced inhibition (RI). Those showing HRI were A(H1N1)pdm09 with NA H275Y (n=169), A(H3N2) with NA E119V (n=1), B/Victoria-lineage with NA E117G (n=1) and B/Yamagata-lineage with NA H273Y (n=1); amino acid position numbering is A subtype and B type specific. Although approximately 98% of circulating viruses tested during the 2013–2014 period were sensitive to all four NAIs, a large community cluster of A(H1N1)pdm09 viruses with the NA H275Y substitution from patients with no previous exposure to antivirals was detected in Hokkaido, Japan. Significant numbers of A(H1N1)pdm09 NA H275Y viruses were also detected in China and the United States: phylogenetic analyses showed that the Chinese viruses were similar to those from Japan, while the United States viruses clustered separately from those of the Hokkaido outbreak, indicative of multiple resistance-emergence events. Consequently, global surveillance of influenza antiviral susceptibility should be continued from a public health perspective.</abstract><cop>Netherlands</cop><pub>Elsevier B.V</pub><pmid>25721488</pmid><doi>10.1016/j.antiviral.2015.02.003</doi><tpages>12</tpages><orcidid>https://orcid.org/0000-0002-9064-4699</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0166-3542
ispartof Antiviral research, 2015-05, Vol.117, p.27-38
issn 0166-3542
1872-9096
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9036627
source MEDLINE; ScienceDirect Journals (5 years ago - present)
subjects Acids, Carbocyclic
Amino Acid Substitution
Antiviral Agents - pharmacology
Antiviral resistance
China - epidemiology
Cyclopentanes - pharmacology
Disease Outbreaks - statistics & numerical data
Drug Resistance, Viral - genetics
Enzyme Inhibitors - pharmacology
Europe - epidemiology
Global analysis
Guanidines - pharmacology
Humans
Influenza A Virus, H1N1 Subtype - drug effects
Influenza A Virus, H1N1 Subtype - genetics
Influenza A Virus, H3N2 Subtype - drug effects
Influenza A Virus, H3N2 Subtype - genetics
Influenza B virus - drug effects
Influenza B virus - genetics
Influenza virus
Inhibitory Concentration 50
Japan - epidemiology
Microbial Sensitivity Tests
Neuraminidase - antagonists & inhibitors
Neuraminidase - chemistry
Neuraminidase - genetics
Neuraminidase inhibitors
Oseltamivir
Oseltamivir - pharmacology
Phylogeny
Pyrans
Reduced susceptibility
Sialic Acids
Time Factors
United States - epidemiology
World Health Organization
Zanamivir - analogs & derivatives
Zanamivir - pharmacology
title Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2013–2014
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-15T12%3A52%3A11IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Global%20update%20on%20the%20susceptibility%20of%20human%20influenza%20viruses%20to%20neuraminidase%20inhibitors,%202013%E2%80%932014&rft.jtitle=Antiviral%20research&rft.au=Takashita,%20Emi&rft.date=2015-05-01&rft.volume=117&rft.spage=27&rft.epage=38&rft.pages=27-38&rft.issn=0166-3542&rft.eissn=1872-9096&rft_id=info:doi/10.1016/j.antiviral.2015.02.003&rft_dat=%3Cproquest_pubme%3E1732833252%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1732833252&rft_id=info:pmid/25721488&rft_els_id=S0166354215000315&rfr_iscdi=true